Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis
Advanced Science · 2023
DOI: 10.1002/advs.202206584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Mingli Li und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc, Sarcoma, Ewing. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Sarcoma Foundation of America.
Abstract (Originalsprache)
Epigenetic dysregulation is reported in multiple cancers including Ewing sarcoma (EwS). However, the epigenetic networks underlying the maintenance of oncogenic signaling and therapeutic response remain unclear. Using a series of epigenetics‐ and complex‐focused CRISPR screens, RUVBL1, the ATPase component of NuA4 histone acetyltransferase complex, is identified to be essential for EwS tumor progression. Suppression of RUVBL1 leads to attenuated tumor growth, loss of histone H4 acetylation, and ablated MYC signaling. Mechanistically, RUVBL1 controls MYC chromatin binding and modulates the MYC‐driven EEF1A1 expression and thus protein synthesis. High‐density CRISPR gene body scan pinpoints the critical MYC interacting residue in RUVBL1. Finally, this study reveals the synergism between RUVBL1 suppression and pharmacological inhibition of MYC in EwS xenografts and patient‐derived samples. These results indicate that the dynamic interplay between chromatin remodelers, oncogenic transcription factors, and protein translation machinery can provide novel opportunities for combination cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
- Division of Epigenetic and Transcriptional Engineering, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
- City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.
- Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, 06510, USA.
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
- School of Biosystems and Biomedical Sciences, College of Health Science, Korea University, Seoul, 02841, South Korea.
ORCID-Profile: Chun-Wei Chen
Förderung
- NCI NIH HHS
- NIH HHS
- Sarcoma Foundation of America
- American Society of Hematology
- National Institutes of Health
Zitieren
APA
Li, M., Yang, L., Chan, A. K. N., Pokharel, S. P., Liu, Q., Mattson, N., Xu, X., Chang, W. H., Miyashita, K., Singh, P., Zhang, L., Li, M., Wu, J., Wang, J., Chen, B., Chan, L. N., Lee, J., Zhang, X. H., Rosen, S. T., …, & Chen, C. W. (2023). Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis. Advanced Science. https://doi.org/10.1002/advs.202206584
Vancouver
Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, et al. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis. Advanced Science. 2023. doi:10.1002/advs.202206584
BibTeX
@article{Li2023,
author = {Li, Mingli and Yang, Lu and Chan, Anthony K N and Pokharel, Sheela Pangeni and Liu, Qiao and Mattson, Nicole and Xu, Xiaobao and Chang, Wen-Han and Miyashita, Kazuya and Singh, Priyanka and Zhang, Leisi and Li, Maggie and Wu, Jun and Wang, Jinhui and Chen, Bryan and Chan, Lai N and Lee, Jaewoong and Zhang, Xu Hannah and Rosen, Steven T and Müschen, Markus and Qi, Jun and Chen, Jianjun and Hiom, Kevin and Bishop, Alexander J R and Chen, Chun-Wei},
title = {Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202206584}
}
EUVIMED